Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection-Reference-Cited by-同舟云学术

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

Published:2020-05-03 Issue:2-3 Volume:21 Page:83-89
ISSN:2578-7489
Container-title:HIV Research & Clinical Practice
language:en
Short-container-title:HIV Research & Clinical Practice

Author:

Lathouwers Erkki¹,Seyedkazemi Sareh²^ORCID,Luo Donghan³,Brown Kimberley³,De Meyer Sandra¹,Wong Eric Y.²^ORCID

Affiliation:

1. Janssen Pharmaceutica NV, Beerse, Belgium

2. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

3. Janssen Research & Development, LLC, Titusville, NJ, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/25787489.2020.1794439

Reference30 articles.

1. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 24, 2019.

3. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy

4. Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication;DARU Journal of Pharmaceutical Sciences;2024-07-19

2. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective;Antiviral Therapy;2023-09-25

3. Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance;AIDS Research and Therapy;2021-09-08

4. Antiretroviral Resistance;Fundamentals of HIV Medicine 2021;2021-06

5. Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis;HIV Research & Clinical Practice;2021-03-04